BURL 42.32 Burlington Stores Inc $BURL Hit a 52 week high

New Post Public Reply Private Reply Replies (0) Message Board
DennyT
BURL 42.32 Burlington Stores Inc $BURL Hit a 52 week high of 43.00 Currently at 42.32 -0.56 -1.31% With a day low of 42.17 and a total volume of 302,000.

BURL Burlington Stores Inc Recent Headline News

Macy's Stores Coming to Abu Dhabi - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:15PM CDT
Macy's, Inc. (M) is slated to open its first namesake store in Abu Dhabi's swanky new shopping center along with a Bloomingdale's outlet in 2018.
BGFV: 12.95 (+0.27), M: 59.88 (+0.84), BURL: 42.32 (-0.56), ROST: 81.41 (-0.47)

Family Dollar Troubled by Stiff Competition, Tight Spending - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 4:56PM CDT
Family Dollar's (FDO) troubles continue, as it delivered another dismal quarterly performance. Management blamed the quarter's debacle on stiff competition and cautious consumer spending.
DLTR: 61.56 (-0.55), BURL: 42.32 (-0.56), FDO: 78.84 (+0.15), ROST: 81.41 (-0.47)

Sears Up Big on $625M Rights Offering, Primark Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Oct 21, 3:37PM CDT
Shares of Sears Holdings Corporation (SHLD) gained over 23% yesterday after the cash-strapped broad-line retailer made two announcements in a bid to enhance its financial flexibility and improve operating performance.
TJX: 64.00 (-0.56), BURL: 42.32 (-0.56), SHLD: 42.81 (+10.14), ROST: 81.41 (-0.47)

Costco Enters Chinese Market via Alibaba's Tmall Global - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 6:08PM CDT
In order to tap the increasing demand for imported products and brands by Chinese consumers, Costco (COST) is foraying into the country in collaboration with Alibaba (BABA).
COST: 137.71 (+0.62), BURL: 42.32 (-0.56), ROST: 81.41 (-0.47), BABA: 114.56 (+2.99)

What Falling Estimates & Price Mean for China Nepstar Chain Drugstore (NPD) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:44AM CDT
China Nepstar Chain Drugstore is a stock to drop as it has witnessed negative trend in earnings estimate revisions and has seen its price decline significantly.
NPD: 1.82 (+0.01), BURL: 42.32 (-0.56), BKS: 22.43 (+0.07), CBD: 40.40 (+0.25)

Family Dollar Traces Q4 Earnings Miss to Stiff Competition - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 8:10AM CDT
Family Dollar (FDO) posted fourth-quarter fiscal 2014 earnings of 73 cents a share that missed the Zacks Consensus Estimate of 77 cents, and plunged 15.1% from 86 cents earned in the prior-year quarter.
DLTR: 61.56 (-0.55), DG: 64.41 (+0.40), BURL: 42.32 (-0.56), FDO: 78.84 (+0.15)

Sears Sees Volatile Day on Halted Vendor Shipment Buzz - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 09, 4:20PM CDT
Shares of Sears Holdings Corporation (SHLD) remained highly volatile throughout yesterday's trading session based on Bloomberg's report of vendors halting merchandise shipments to the company.
COST: 137.71 (+0.62), BURL: 42.32 (-0.56), SHLD: 42.81 (+10.14), ROST: 81.41 (-0.47)

Sears Holding to Raise Fund by Selling Stake in Canada Unit - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 11:20AM CDT
After raising a short-term loan of $400 million from its CEO Edward S. Lampert and his hedge fund ESL Partners L.P. last month, Sears Holdings Corporation (SHLD), has once again geared up to raise $380 million.
COST: 137.71 (+0.62), BURL: 42.32 (-0.56), SHLD: 42.81 (+10.14), ROST: 81.41 (-0.47)

Costco Q4 Earnings Beat on Comps Growth, Revenues Rise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 8:00AM CDT
Costco (COST) has released with its fourth-quarter fiscal 2014 results today. Quarterly earnings of $1.58 per share surpassed the Zacks Consensus Estimate of $1.52.
TGT: 64.17 (+2.28), COST: 137.71 (+0.62), WMT: 78.77 (+0.96), BURL: 42.32 (-0.56)

Burlington Stores, Inc. Announces Secondary Offering of Common Stock
Business Wire - Mon Oct 06, 3:53PM CDT
Burlington Stores, Inc. (NYSE:BURL) (the "Company" announced today that affiliates of Bain Capital Partners, LLC and certain other stockholders intend to offer 8,000,000 shares of the Company's common stock in an underwritten public offering. The offering consists entirely of secondary shares to be sold by the selling stockholders. The Company will not sell any shares in the offering and will not receive any proceeds from the offering.
JPM: 61.47 (+0.24), BURL: 42.32 (-0.56)

Should TJX Companies (TJX) Stock Be in Your Portfolio? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 1:40PM CDT
On Sep 26, 2014, we issued an updated research report on The TJX Companies Inc. (TJX).
TJX: 64.00 (-0.56), BURL: 42.32 (-0.56), FDO: 78.84 (+0.15), ROST: 81.41 (-0.47)

Can PriceSmart Turn Around Revenues with Club Openings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 01, 1:00PM CDT
PriceSmart, Inc. (PSMT) has acquired a site in the Municipality of Chorrera, Panama upon which it expects to build a new warehouse club.
PSMT: 92.45 (+0.22), CTRN: 21.80 (-0.98), BURL: 42.32 (-0.56), FL: 54.50 (+0.03)

Zacks.com featured expert Kevin Matras highlights: Ambarella, Burlington Stores, Providence Service Corp., Team Health Holdings and Vimicro International
PR Newswire - Thu Sep 25, 9:04AM CDT
Stocks in this week's article include: Ambarella (NASDAQ: AMBA - Free Report), Burlington Stores (NYSE: BURL - Free Report), Providence Service Corp. (NASDAQ: PRSC - Free Report), Team Health Holdings (NYSE: TMH - Free Report) and Vimicro International (NASDAQ: VIMC - Free Report). Kevin Matras goes over a Relative Price Change screen to help you find top performers no matter what the market is doing.
PRSC: 38.48 (-0.90), VIMC: 9.06 (+0.17), BURL: 42.32 (-0.56)

How Will Burlington Stores (BURL) Stock Be Affected Today by This Analyst Initiation?
at The Street - Wed Sep 24, 11:13AM CDT
Shares of Burlington Stores (BURL) are up after Credit Suisse initiated coverage of the company with a 'neutral' rating.
BURL: 42.32 (-0.56)

Buy This Momentum Retail Stock Before the Holidays Hit - Stocks in the News
Zacks Research Staff - Zacks Investment Research - Tue Sep 23, 9:30AM CDT
Why Burlington Stores (BURL) could be an an interesting retail stock this holiday season.
BURL: 42.32 (-0.56)

How to Pick Winning Stocks When the Market is Going Down - Screen of the Week
Kevin Matras - Zacks Investment Research - Tue Sep 23, 2:19AM CDT
How to Pick Winning Stocks When the Market is Going Down - Screen of the Week
AMBA: 47.14 (+1.13), PRSC: 38.48 (-0.90), VIMC: 9.06 (+0.17), BURL: 42.32 (-0.56), TMH: 54.14 (-2.70)

GameStop (GME) Issues Senior Notes worth $350 Million - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 11:30AM CDT
GameStop Corp. (GME) recently declared the pricing of senior notes for a public offering, worth $350 million.
GME: 43.69 (-1.04), CTRN: 21.80 (-0.98), BURL: 42.32 (-0.56), FL: 54.50 (+0.03)

Can Burlington Stores (BURL) Stock Continue to Grow Earnings? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:55AM CDT
Burlington Stores is well-positioned for future earnings growth, as the stock has witnessed a double digit earnings growth prospect and also holds an impressive Zacks Rank.
BURL: 42.32 (-0.56)

Gordmans Stores (GMAN) in Focus: Stock Rises 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 7:44AM CDT
Gordmans Stores, Inc. (GMAN) was a big mover last session, as the company saw its shares rise a little over 6% on the day.
GMAN: 3.19 (-0.10), CTRN: 21.80 (-0.98), FL: 54.50 (+0.03), BURL: 42.32 (-0.56)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
EyePoint Lawsuit Puts DURAVYU Claims Under a Microscope

Updated Category News Views 55

Nothing makes biotech investors reach for the aspirin faster than a lawsuit centered on whether a drug worked as advertised. EyePoint, Inc. is facing a proposed federal securities class action alleging that the company overstated the effectiveness of DURAVYU and, by extension, its clinical, regulatory, and commercial prospects. That is a serious allegation, but it remains...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 137

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 410

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 98

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 49

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 191

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 618

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
DKSH's Vietnam Oncology Pact Carries Real Promise, Risk

Updated Category News Views 52

A cancer-market announcement ought to make investors pause before they reach for a spreadsheet. Specialised Therapeutics and DKSH have signed an exclusive partnership to bring oncology therapies into Vietnam, and the human case is painfully clear: the country recorded an estimated 180,000 new cancer cases and more than 120,000 deaths annually in the 2022 GLOBOCAN data....

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 445

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating the Legacy of the Kashi Fair: A Cultural Journey

Updated Category News Views 387

The Kashi Fair: A Living Tribute to the Silk Road The Kashi Fair, also known as the Kashi-Central and South Asia Commodity Fair, has become an essential trade event, connecting cultures and economies while celebrating the essence of the historic Silk Road. For Pakistani businessman Muhammad Abbas, the Managing Director of Pakistan Northern Gems, this annual event in Kashi...

Continue Reading
Global Forum Focuses on Sustainable Future and Cooperation

Updated Category News Views 260

Global Leaders Gather to Discuss a Sustainable Future Under the theme "Collective Action for One Future", a significant forum took place in a vibrant city, bringing together over 130 leaders from various nations. This event marked the ninth edition of an esteemed international gathering focused on transformative issues affecting the worldwide landscape. For the first...

Continue Reading
Blue Onion Secures $10 Million to Enhance Financial Data Management

Updated Category News Views 294

Blue Onion Secures $10 Million Series A Funding In a significant advancement for financial data management, Blue Onion has successfully secured $10 million in a Series A funding round, led by Viola FinTech. This strategic investment aims to broaden Blue Onion's capabilities in delivering accurate and fully reconciled transaction-level data that CFOs can trust. With this...

Continue Reading
Lilly's Retatrutide Outshines Ozempic in Key Diabetes Trial

Updated Category News Views 120

Lilly's Breakthrough in Diabetes Treatment Eli Lilly's retatrutide is stirring up the diabetes treatment waters. The latest Phase 3 comparison to Ozempic's top dose reveals some surprising results. I'm not one to toss out kudos lightly, but this could be a genuine game-changer if things hold steady. A1C Reductions: A Close Look at the Numbers We’re staring down the...

Continue Reading
Investing in Houlihan Lokey: A Decade of Growth Insights

Updated Category News Views 176

Understanding the Investment Journey with Houlihan Lokey Houlihan Lokey (NYSE: HLI) has demonstrated remarkable performance over the past decade. This investment bank has outshined market averages, yielding an impressive annualized return of 22.61%. As of now, Houlihan Lokey boasts a significant market capitalization of $12.57 billion, showcasing its robust standing in...

Continue Reading